Enabling Nanomembrane-Based Biomolecule and Nanoparticle Separations

实现基于纳米膜的生物分子和纳米颗粒分离

基本信息

批准号：
9045849
负责人：
James L McGrath
金额：
$ 19.89万
依托单位：
SIMPORE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-19 至 2018-01-18
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9045849
关键词：
Academia Antibodies Area Biological Sciences Biotechnology Buffers Caliber Centrifugation Complex Custom Data Development Devices Diagnostics Research Dialysis procedure Drug Delivery Systems Goals Housing Immunoglobulin G Laboratories Letters Manufacturer Name Marketing Membrane Methods Molecular Molecular Sieve Chromatography Pain Particle Size Performance Permeability Phase Polymers Polystyrenes Preparation Proteins Quantum Dots Reporting Resort Sampling Scheme Scientist Silicon Small Business Technology Transfer Research Specificity Speed Surface Techniques Technology Testing Time Tissues Tube Universities antibody conjugate base biomedical scientist design drug development experience in vivo imaging innovation meetings nanomembrane nanoparticle particle product development professor prototype public health relevance solute tool

项目摘要

DESCRIPTION (provided by applicant): The global market for nanoparticles (NP) in biotechnology, drug development and drug delivery was estimated to be $20B for 2013 and is expected to reach more than $50B by 2017. The two most active areas of product development are NPs for drug delivery and for in vivo imaging. In these applications it is often critical that he outer surfaces of NPs are functionalized with antibodies (Ab) that target them to speciﬁc tissues After functionalizing NPs with Abs, it is necessary to remove unbound Ab from the NP preparation because any free Ab will compete with the NPs for target tissues. Given the similar sizes of Ab (~ 14 nm) and NPs, this ubiquitous clean-up step is challenging and represents a current pain in the market place. Both academic and industrial NP scientists report that existing polymer- based membranes are not capable of performing this separation and that they must resort to more time-consuming, complex, and lower yield techniques such as size-exclusion chromatography or dialysis. Membrane-based methods are preferred because of their simplicity, efﬁciency and scalability. In this proposal, we will realize a near-term, straight-forward produc development opportunity that will result in a solution to the NP-Ab separation problem. Using SiMPore's nanomembranes in a custom centrifuge conﬁguration, we have recently shown the ability to separate Ab from 20 nm polystyrene particles. Additional innovations in membrane fabrication and non-fouling coatings will allow us to pursue the following goals: 1) to develop and evaluate a SiMPore product prototype based on our preliminary custom centrifuge concept, 2) to produce a sufﬁcient number of prototypes to enable beta- testing at two major life science tool suppliers, and 3) to introduce a validated product upon completion of this 9-month Phase I project.

描述（由应用程序提供）：纳米颗粒的全球市场（NP）在生物技术，药物开发和药物输送估计为2013年为20B美元，预计到2017年将达到50B美元以上。产品开发的两个最活跃的领域是用于药物输送和体内成像的NPS。在这些应用中，至关重要的是，NP的外表面与抗体（AB）功能化，该抗体（AB）在用ABS功能化NP后将其靶向特定组织，因此有必要从NP制备中删除Unbound AB，因为任何自由AB都会与NP竞争NP的目标组织。鉴于AB（〜14 nm）和NP的类似尺寸，这种无处不在的清理步骤具有挑战性，代表了当前市场上的痛苦。学术和工业NP科学家都报告说，现有的基于聚合物的机制无法进行这种分离，并且必须诉诸于更耗时，复杂和较低的产量技术，例如尺寸 - 分类色谱或透析。由于其简单，效率和可扩展性，因此优选基于膜的方法。在此提案中，我们将实现近期直接的生产开发机会，这将导致解决NP-AB分离问题的解决方案。在自定义离心机配置中，使用Simpore的纳米膜，我们最近显示了将AB与20 nm聚苯乙烯颗粒分离的能力。 Additional innovations in membrane fabrication and non-fouling coatings will allow us to pursue the following goals: 1) to develop and evaluate a SiMPore product prototype based on our preliminary custom centrifuge concept, 2) to produce a sufﬁcient number of prototypes to enable beta- testing at two major life science tool suppliers, and 3) to introduce a validated product upon completion of this 9-month Phase I project.